Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia

Leukemia

Volumn 11, Issue SUPPL. 1, 1997, Pages 1-6

  Momparler, R L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

5 Aza 2 deoxycytidine; Chemotherapy; DNA methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL CYCLE PARAMETERS; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CONFERENCE PAPER; DEMETHYLATION; DNA METHYLATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; ENZYME KINETICS; GENE ACTIVATION; GENE THERAPY; GRANULOCYTOPENIA; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LEUKEMIA CELL; LEUKOPENIA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030938184     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Sorm F, Vesely J. Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 1968; 15: 339-343.
2. Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-Aza-2′-deoxycytidine, 1-β-o-arabinofuranosyl-cytosine and 5-azacytidine against L1210 leukemia. Leukemia Res 1984; 8: 1043-1049.